In-vitro diagnostics instruments market to reach $99.44 billion by 2030

The in-vitro diagnostics instruments market is projected to grow from $61.09 billion in 2025 to $67.18 billion in 2026, then climb to $99.44 billion by 2030, according to a new report from The Business Research Company. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region as chronic disease testing and molecular diagnostics expand.

Why it matters: - In-vitro diagnostics instruments help detect, diagnose, monitor and manage disease from samples such as blood, urine and tissue outside the body. - The market’s growth tracks rising demand for earlier detection, continuous monitoring and more personalized care. - Chronic and lifestyle-related diseases are increasing the need for diagnostic tools across healthcare systems.

What happened: - The Business Research Company released its In-Vitro Diagnostics Instruments Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 on Aug. 13, 2026. - The report sizes the global market at $61.09 billion in 2025. - The market is projected to reach $67.18 billion in 2026, implying 10.0% annual growth. - The report forecasts the market will climb to $99.44 billion by 2030, at a 10.3% CAGR.

The details: - Growth in the historical period has been driven by chronic disease prevalence, stronger hospital laboratory infrastructure, better diagnostic reagents, rising awareness of early detection and government healthcare initiatives. - Future growth is expected to come from molecular diagnostics, personalized medicine, AI in diagnostic workflows, healthcare infrastructure expansion in emerging markets and demand for home-based testing. - The report highlights point-of-care testing, personalized diagnostics, rapid molecular testing, remote patient monitoring and compact laboratory instruments as key trends. - In-vitro diagnostics instruments analyze biological samples outside the human body and support clinical decision-making with fast laboratory results. - The report says chronic conditions such as heart disease, diabetes, obesity and some cancers are pushing demand for early detection and ongoing monitoring. - In 2024, the American Action Forum said nearly 60% of US adults live with at least one chronic condition, while 40% manage multiple conditions. - The same source projected that share could nearly double by 2050. - The chronic disease treatment market is forecast to reach $38.02 billion by 2034, up from $9.74 billion in 2025. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - More information is available in the full report and a free sample.

Between the lines: - The market outlook suggests diagnostics is moving from a lab-centered category toward faster, more distributed testing. - AI, remote monitoring and home-based tools point to a broader shift in where and how patients are tested. - The regional split shows mature markets still dominate revenue, while emerging markets are likely to drive the next leg of expansion.

What's next: - Adoption of molecular testing and point-of-care tools is expected to keep accelerating through 2030. - Demand for compact instruments and home testing should grow as healthcare providers and patients seek faster access to results. - The report frames Asia-Pacific as the main growth engine to watch over the forecast period.